Actavis launches pantoprazole generic in three EU markets
This article was originally published in Scrip
Actavis has launched a generic version of Nycomed's proton pump inhibitor pantoprazole (Protium/Pantoloc) in Germany, Ireland and the Netherlands, following expiry of patent protection in those markets on May 6th.
You may also be interested in...
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.